Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $2.6 million.

  • Zhengye Biotechnology Holding's Cash & Equivalents changed N/A to $2.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.6 million, marking a year-over-year change of. This contributed to the annual value of $2.6 million for FY2024, which is 2139.2% up from last year.
  • Latest data reveals that Zhengye Biotechnology Holding reported Cash & Equivalents of $2.6 million as of Q2 2025.
  • Zhengye Biotechnology Holding's 5-year Cash & Equivalents high stood at $2.6 million for Q4 2024, and its period low was $2.1 million during Q4 2023.
  • Over the past 3 years, Zhengye Biotechnology Holding's median Cash & Equivalents value was $2.6 million (recorded in 2025), while the average stood at $2.4 million.
  • Data for Zhengye Biotechnology Holding's Cash & Equivalents shows a peak YoY increase of 2371.78% (in 2024) and a maximum YoY decrease of 2371.78% (in 2024) over the last 5 years.
  • Zhengye Biotechnology Holding's Cash & Equivalents (Quarter) stood at $2.1 million in 2023, then increased by 23.72% to $2.6 million in 2024, then dropped by 0.68% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q2 2025, $2.6 million for Q4 2024, and $2.1 million during Q4 2023.